Group 1: Company Strategy and Market Focus - In 2026, the company will focus on stabilizing its existing business and driving innovation through a dual approach, emphasizing both hospital and external markets [2][3] - Key products in the external market include Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, and other newly acquired exclusive varieties [4] - The company aims to enhance brand recognition and terminal coverage through the new "JiuDian Pain Relief" brand image [2] Group 2: Innovation and Product Development - The company will continue to adopt a strategy of "independent research and project introduction" for innovative drugs, actively seeking competitive projects [5] - Plans to enrich the product pipeline through collaborative research and development, as well as industry-academia transformation [5] Group 3: Financial Outlook and Shareholder Returns - The company will develop a scientific and sustainable shareholder return plan over the next 2-3 years based on operational performance and market conditions [8] - There is a potential for further acquisitions to enhance the product line and business layout as needed [8] Group 4: Market Challenges and Pricing Impact - The implementation of centralized procurement for Loxoprofen Sodium Gel Patch may lead to a temporary decrease in gross margin due to price adjustments [7] - The company will maintain a stable overseas business primarily focused on the export of raw materials and pharmaceutical excipients [6]

Group 1: Product Matrix and Market Position - The company has established a clear and advantageous external product matrix, with significant exclusive and medical insurance advantages in key varieties. Approved products include: Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, Anti-inflammatory Pain Relief Patch, Lidocaine Gel Patch, Strong Waist and Bone Strengthening Patch, and Daiwen Moxibustion Patch [2] - The Ketoprofen Gel Patch is a key exclusive product with significant market competitiveness, while the Daiwen Moxibustion Patch holds both traditional Chinese medicine exclusivity and medical insurance exclusivity, showcasing distinct advantages [2] Group 2: Brand Development Strategies - The company has implemented a series of systematic and innovative measures to enhance brand influence and market recognition, including expanding into retail pharmacies and online platforms [3] - A brand upgrade event was held on December 6, 2025, introducing the "JiuDian Pain Relief Expert" symbol and the slogan "Change to JiuDian for Pain Relief Patches," aimed at addressing consumer pain points and enhancing brand communication and market competitiveness [3] Group 3: Sales and Procurement Expectations - The 11th batch of national centralized procurement results will be executed nationwide starting February 2026, with procurement cycles lasting until December 31, 2028 [3] - The company is optimistic about the market prospects for the Ketoprofen Gel Patch, which was approved for listing in 2023 and successfully entered the national medical insurance directory [3] Group 4: Innovation in Drug Development - The company is undergoing a comprehensive transformation towards innovative drug research and development, utilizing a strategy of multiple R&D centers and various drug forms [4] - Two innovation drug R&D centers are being established in central and Yangtze River Delta regions, leveraging local clinical resources and cost advantages [4] - The company is focusing on various tumor and chronic disease indications, employing small molecule drugs, peptide drugs, PDC, and ADC formats [4] Group 5: New Drug Advantages - The newly introduced small molecule pain relief innovative drug YJ2301 is designed to overcome limitations of existing neurogenic pain medications, such as limited efficacy and significant side effects [4] - Clinical pre-research data for YJ2301 shows superior pain relief effects and the potential to address issues like drowsiness and tolerance, providing a new solution for neurogenic pain management [4]

Group 1: Company Overview and Market Performance - The company, Hunan Jiutian Pharmaceutical Co., Ltd., reported stable operations in Q4 2025, with sales activities proceeding as planned [2] - The pharmaceutical manufacturing industry saw a revenue of CNY 12,275.2 billion in the first half of 2025, a year-on-year decrease of 1.2%, and a profit total of CNY 1,766.9 billion, down 2.8% [2] - The transdermal patch market is projected to exceed CNY 7 billion in sales in 2024, with a year-on-year growth of approximately 10%, and over CNY 4 billion in the first half of 2025, reflecting a 15% increase [3] Group 2: Product Development and Competitive Landscape - The external pain relief market is expanding due to increasing health demands and an aging population, presenting significant growth opportunities [4] - The company emphasizes R&D as a driving force, leveraging its technological expertise in gel patches to enhance product quality and brand influence [4] - The company has developed a clear and competitive external product matrix, including unique products like Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, which have significant market advantages [9] Group 3: Brand Strategy and Market Penetration - The company is implementing innovative brand strategies to enhance market recognition, including a brand upgrade event on December 6, 2025, introducing the "Jiutian Pain Relief Expert" branding [5] - The brand slogan "Pain Relief Patch, Choose Jiutian" aims to address consumer pain points and strengthen brand credibility [5] Group 4: Financial Implications and Strategic Acquisitions - The centralized procurement of Loxoprofen Sodium Gel Patch may lead to a temporary adjustment in profit margins, impacting short-term revenue and profit performance [6][7] - The acquisition of 67 drug approvals through the subsidiary Nona Pharmaceutical aims to stabilize sales and fill potential gaps caused by procurement changes [8] Group 5: Innovation and Future Directions - The company is transitioning towards innovative drug development, establishing R&D centers in central and Yangtze River Delta regions to leverage clinical resources and cost advantages [10][11] - The focus is on various cancer and chronic disease treatments, utilizing multiple drug forms and collaborative research models to enhance core competitiveness in the innovative drug sector [11]

Core Viewpoint - The company, through its subsidiary Nona Pharmaceutical, has acquired 67 drug approvals, including 8 exclusive products, which are expected to enhance its sales and stabilize performance [2] Group 1: Acquisition Details - The acquisition includes key products such as Daiwen Jiao Gao, which has unique advantages in medical insurance, helping to fill potential sales gaps from the company's participation in centralized procurement of Loxoprofen Sodium Gel [2] - The company aims to leverage its existing sales channels to achieve rapid growth in sales for the newly acquired products [2] Group 2: Strategic Implications - The introduction of differentiated categories such as traditional Chinese medicine external preparations will further enhance the company's treatment portfolio [2] - This strategic move is expected to stabilize the company's performance amidst potential challenges in the market [2]